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Abstract
Background: Drug-resistant tuberculosis (TB) is a major threat to global public health. Patients with extensively drug-
resistant TB (XDR-TB), particularly those with HIV-coinfection, experience high and accelerated mortality with limited
available interventions. To determine modifiable factors associated with survival, we evaluated XDR-TB patients from a
community-based hospital in rural South Africa where a large number of XDR-TB cases were first detected.
Methodology/Principal Findings: A retrospective case control study was conducted of XDR-TB patients diagnosed from
2005–2008. Survivors, those alive at 180 days from diagnostic sputum collection date, were compared with controls who
died within 180 days. Clinical, laboratory and microbiological correlates of survival were assessed in 69 survivors (median
survival 565 days [IQR 384–774] and 73 non-survivors (median survival 34 days [IQR 18–90]). Among 129 HIV+ patients,
multivariate analyses of modifiable factors demonstrated that negative AFB smear (AOR 8.4, CI 1.84–38.21), a lower
laboratory index of routine laboratory findings (AOR 0.48, CI 0.22–1.02), CD4.200 cells/mm
3 (AOR 11.53, 1.1–119.32), and
receipt of antiretroviral therapy (AOR 20.9, CI 1.16–376.83) were independently associated with survival from XDR-TB.
Conclusions/Significance: Survival from XDR-TB with HIV-coinfection is associated with less advanced stages of both
diseases at time of diagnosis, absence of laboratory markers indicative of multiorgan dysfunction, and provision of
antiretroviral therapy. Survival can be increased by addressing these modifiable risk factors through policy changes and
improved clinical management. Health planners and clinicians should develop programmes focusing on earlier case finding
and integration of HIV and drug-resistant TB diagnostic, therapeutic, and preventive activities.
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Introduction
Drug-resistant tuberculosis (TB) has emerged as a major threat
to global public health. In 2006, a large number of cases of
extensively drug-resistant tuberculosis (XDR-TB), newly defined
as resistance to isoniazid, rifampin, any fluoroquinolone and an
injectable antimicrobial agent (kanamycin, amikacin, or capreo-
mycin), were reported from a district hospital in Tugela Ferry, a
rural site in KwaZulu Natal province, South Africa [1]. Initially,
53 XDR-TB cases were characterized by HIV-coinfection with
accelerated and near-complete (98%) mortality; median survival
from sputum collection was 16 days [1]. XDR-TB has since been
reported throughout South Africa [2], in neighboring sub-Saharan
African countries and in 58 countries worldwide [3] and
jeopardizes both TB and antiretroviral therapy (ART) treatment
programmes globally [4]. South Africa is among the countries with
the greatest burden of drug-resistant TB including XDR-TB [5].
By year-end 2008, 463 patients from Tugela Ferry had been
diagnosed with XDR-TB. Though the mortality rate has fallen, it
remains extremely high (82%) and rapid for most patients with a
median time to death after sputum collection of 28.5 days [6].
Information regarding survival and outcomes of patients with
XDR-TB remains both limited and inconsistent. Accelerated and
high mortality from XDR-TB in Tugela Ferry, where HIV-
coinfection exceeds 90%, contrasts with reports from other
geographic areas where XDR-TB-related mortality in patients
without HIV-coinfection, has ranged from 7%–48%[1,7,8,9,10].
In a more recent series of XDR-TB patients from a TB specialty
referral hospital in South Africa, the HIV-coinfection rate was
substantially lower (47%) than that reported from Tugela Ferry
and 3-month mortality rates were more favorable [11].
Despite considerable attention from public health planners,
programme officials, and clinicians regarding the management
of XDR-TB, there are limited empirical data regarding the
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e31786management of XDR-TB and HIV-coinfection and little insight
into factors associated with survival. The increase in XDR-TB
cases and recently observed improved survival in Tugela Ferry
now provides a unique opportunity to determine correlates of
survival among XDR-TB patients from a single non-referral
community-based hospital. In this study, we focus on modifiable
factors that may be associated with improved XDR-TB survival.
Methods
We performed a retrospective case control study of patients with
XDR-TB from Tugela Ferry, South Africa from 2005–2008.
Setting
Tugela Ferry is a rural, resource-limited community in
KwaZulu Natal province, South Africa, with 180,000 traditional
Zulu people living in widely dispersed compounds extending over
2000 square kilometers. Most people lack access to potable water
(69%) or electricity (69%) and unemployment is high (85%) [12].
The 350-bed district government Church of Scotland Hospital
(COSH) and its 15 primary health care clinics provide health care
for this district. TB DOTS and HIV services began in 1995 and
2003, respectively. TB incidence is 1054/100,000 [13] and HIV
prevalence among pregnant women exceeds 30%[14].
Ethics Statement
The study was approved by institutional review boards at both
University of KwaZulu Natal in Durban, South Africa and Yale
University in New Haven, Connecticut. The data reviewed and
presented in this study was originally collected in medical records
as part of routine clinical care. Informed consent was not
requested of patients since recording of data into the medical
charts was for the purpose of regular medical care. The ethics
committees waived the requirement for informed consent for this
retrospective study given that the use of previously collected
routine clinical data did not present further risk to patients.
Management of TB and HIV
Initial TB diagnosis and treatment initiation was based on
sputum acid-fast bacilli (AFB) smear, chest radiograph and clinical
judgment. Sputum culture was usually obtained for treatment
relapse, treatment failure, or persistently positive AFB at the end of
the intensive phase of treatment, rather than at primary diagnosis
[15]. After recognition of drug-resistant TB in 2006, cultures at
COSH could be ordered during the initial TB diagnosis. Category
1 TB treatment using isoniazid (INH), rifampin (Rif), ethambutol,
and pyrazinamide for the 2-month intensive phase was followed by
a 4-month continuation phase using INH/Rif [16]. Ziehl-Neelsen
microscopy of sputum was performed locally at COSH while
auramine smear, culture, and drug susceptibility testing (DST)
(isoniazid, rifampin, ethambutol, streptomycin, ciprofloxacin,
kanamycin) were performed at the provincial referral laboratory
in Durban using previously described methods [1]. Typically,
culture and DST results were available after 2–3 months.
Microbiologically-confirmed XDR-TB patients were traced by
the local DOTS office and if alive, referred to the provincial TB
specialty referral hospital, King George V (KGV), in Durban, to
initiate XDR-TB treatment - a process requiring a minimum of
several months from diagnostic sputum collection. The standard-
ized intensive phase regimen for XDR-TB consisted of ethambu-
tol, pyrazinamide, ethionamide, cycloserine or terizidone, para-
aminosalicylic acid, and capreomycin - supervised within an
inpatient unit for a minimum of 6 months. The latter two agents
became available only in late 2007. Capreomycin injections were
discontinued during the continuation phase, and the remaining
oral regimen maintained for a minimum of 18 months with
monthly assessments in Durban. South African guidelines through
2009 provided ART for individuals whose CD4 cell count was less
than 200 cells/mm
3, using regimens combining stavudine and
lamivudine with either efavirenz or nevirapine [15]. An alternative
regimen of once-daily lamivudine, didanosine and efavirenz was
used in selected cases [17]. HIV and TB care were integrated
within the same clinic in Tugela Ferry while physically and
administratively distinct within KGV.
Study Subjects and Definitions
All patients meeting standardized microbiological definition of
XDR-TB identified from culture records and TB DOTS offices
for the 4-year period from January 1, 2005 through December 31,
2008 were eligible for inclusion. Survival was defined as living
.180 days from the date of sputum collection confirming XDR-
TB. Non-survivors were those XDR-TB patients living ,180 days
from sputum collection. The two groups were compared to
identify modifiable factors associated with survival at 180 days.
The median survival was calculated for both groups based on
known outcome data censored on March 31, 2009.
Of the 463 eligible patients with XDR-TB, 69 (14.9%) met the
survival case definition. From the remaining 395 non-survivors,
subjects were reviewed based on availability of medical records.
Seventy-three non-survivors’ charts were available for review,
resulting in 142 patients with XDR-TB available for analysis
(Figure 1).
Inpatient and outpatient records were reviewed using a
standardized data collection instrument that included demograph-
ic, clinical features, laboratory findings, and health-related
outcomes. CD4 counts were considered as baseline if collected
within 90 days of initial sputum confirming XDR-TB. TB cases
were defined as ‘‘initial’’ if they had not previously been treated for
TB and ‘‘recurrent’’ if they had previously completed a course of
treatment before their XDR-TB diagnostic sputum collection.
Cases that had prior confirmed MDR-TB and were receiving
MDR-TB therapy were included. An additive laboratory clinical
severity index (LCSI) was created from data collected at the time
of sputum collection, consisting of abnormal values: hemoglobin
(,13 gm/dL); creatinine (.53 mg/mL); albumin (,35 g/mL);
and alkaline phosphatase (98 IU/mL) to explore the relationship
of these indicators individually and collectively from sputum
collection to the 180-day survival point. A value of ‘‘1’’ was
assigned for each result that was outside the limits of normal
and added together resulting in a count of possible observed
abnormalities from 0 to 4.
Analytic Plan
Frequencies for demographic characteristics and medians with
interquartile ranges (IQR) for clinical and laboratory parameters
were calculated. The primary outcome was survival from XDR-TB.
Student’s t-test, Kruskal-Wallis, and Mantel-Haenszel Chi square of
potential independent variables were assessed using SAS version 9.1
(Cary, NC) to comparesurvivors and non-survivors. The mean LCSI
score was compared for survivors and non-survivors. Given several
variables with a large amount of missing data, the missing completely
at random (MCAR) assumption was assessed for the variables in the
final multivariate model using Little’s test (SPSS 18.0). When .5% of
values were missing, they were suggested to be missing completely at
random and were not related to survival (p.0.71). [17] Based on the
interest in identifying modifiable factors affecting survival, we first
characterized all variables affecting XDR-TB survival as modifiable
or non-modifiable (Figure 2); only those modifiable variables
Modifiable Characteristics for XDR-TB Survival
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multivariate logistic regression analysis. XDR-TB treatment variables
were determined to be confounders with the definition of survival
(alive at 180 days) and were not included in multivariate analysis. A
backward stepwise elimination multivariate logistic regression was
applied using the ‘step’ function for model selection in R using the
Generalized Linear Model framework [18] (version 2.7, Foundation
for Statistical Computing, Vienna, Austria, http://www.r-project.
org). The standard logit link function and the Akaike Information
Criteria (AIC) in R were utilized for model selection; the model with
lowest AIC was selected. [19] The Hosmer-Lemeshow and the
Nagelkerke R
2 tests were used to assess goodness of fit of the final
model. Four modifiable variables, found to be significantly related to
180-day survival among HIV-infected patients, were subjected to
Kaplan-Meier estimates for the dependent variable of survival, using
the ‘‘survfit’’ with the R ‘‘survival’’ package. [20] A logrank test in R
was used to test the difference; proportional hazard calculation was
performed to illustrate the increasing hazard of death in XDR-TB
patients with increasing LCSI score.
Results
Demographic characteristics of the 142 selected subjects did not
differ from the 463 total XDR-TB patients diagnosed during this
period (data not shown). Non-survivors (n=73) reviewed were not
significantly different in age or gender from overall non-survivors
(n=394). The median survival after data censoring was 565 days
(IQR 384–784) in survivors and 34 days (IQR 18–90) in non-
survivors (p,0.0001). Sixty-two (43.7%) XDR-TB patients
presented with a first episode of TB, while 79 (55.6%) previously
had completed therapy for drug-susceptible TB. Of the non-
survivors reviewed, 42 (57.5%) had already died by the time the
culture and DST results were received. Of survivors at the point of
censoring, 52 (75%) had already reached 1 year of observation and
20 (28.9%) had been observed for 2 years of follow-up.
There was no significant difference in proportion of women,
(64%), median age (34 years, IQR 30–35), or proportion HIV-
infected (90.8%) between survivors (n=61, 89.7%) and non-
survivors (n=68, 94.4%). Survivors and non-survivors did,
however, differ on a number of important characteristics
(Table 1). Non-survivors were significantly more likely than
survivors to present with XDR-TB as their initial TB episode
(53.4% vs 33.3%, p=0.02). Laboratory parameters differed
significantly between survivors and non-survivors. Survivors
demonstrated significantly better laboratory values and LCSI
scores, including higher hemoglobin and albumin levels, fewer
renal and liver abnormalities and fewer metabolic disturbances.
The mean LCSI was 1.28 in survivors and 2.22 in non-survivors
Figure 1. Selection of Charts for Review.
doi:10.1371/journal.pone.0031786.g001
Modifiable Characteristics for XDR-TB Survival
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negative auramine smears when compared to non-survivors, and
survivors’ sputum cultures grew more slowly with results reaching
clinicians later than those of non-survivors. Survivors had
significantly less six-drug resistance on standard drug susceptibility
testing.
XDR-TB patients received first-line TB therapy for a median
duration of 16.9 weeks prior to sputum collection with no
difference between survivors and non-survivors. Among the 95
patients who were already receiving first-line therapy at the time of
sputum collection, only 26 (27%) received streptomycin prior to
sputum collection though the majority of reviewed XDR-TB
patients (n=120, 84.5%) demonstrated streptomycin resistance on
DST. Only 12 (8.5%) of the 142 XDR-TB patients received
treatment for culture-confirmed MDR-TB prior to the XDR-TB
sputum collection. With regards to XDR-TB therapy, nearly all
survivors (95.7%) lived long enough to be referred to the provincial
TB referral hospital (KGV) for standardized XDR-TB therapy. In
contrast, 72.6% of non-survivors died before they could be
referred and receive specific therapy. Among the study cohort, 86
(60.5%) patients initiated XDR-TB therapy a median of 2.9
months (2.3–3.8) after sputum collection; documented conversion
to negative sputum culture occurred in 32 (47%) survivors and in
only one of the non-survivors.
HIV-specific measures and ART treatment experience differed
between survivors and non-survivors. Median baseline CD4 cell
counts of survivors were significantly higher than that of non-
survivors (181 vs 83.5 cells/mm
3, p=0.02). Among XDR-TB
patients with HIV-coinfection, survivors were almost twice as
likely to ever receive ART compared to non-survivors (80.3% vs
41.2%, p=0.02). In Kaplan-Meier analyses, CD4 count .200
cells/mm
3 and ART initiation were significantly associated with
survival (Figure 3). Among the 31 survivors who initiated ART
and had repeat CD4 cell count testing after XDR-TB diagnosis,
the median CD4 cell count increased 155 cells/mm
3 (IQR 78–
201). Among the 33 survivors who had subsequent HIV viral load
testing, 23 (69.7%) were undetectable (VL,25 copies/mL).
Multivariate regression analysis was performed for all XDR-TB
patients regardless of HIV status, demonstrating that negative
auramine sputum smear, the number of weeks to a positive sputum
culture, and a low LCSI score (less organ dysfunction) were
associated with survival. For patients with XDR-TB and HIV
coinfection, multivariate regression analysis revealed several
independent correlates of survival, including negative auramine
sputum smear, CD4.200 cells/mm
3 at diagnostic sputum
collection, and the receipt of ART (Table 2). Though highly
significant on univariate analysis, the LCSI, a marker of clinical
severity, approached significance on multivariate analysis
(p=0.056). Kaplan-Meier probabilities of survival differed for
each modifiable factor (Figure 3).
Discussion
To our knowledge, this is the largest sample of XDR-TB
patients from a community-based, non-specialty hospital setting in
sub-Saharan Africa. Although only 69 of the first 463 XDR-TB
patients lived to 180 days (14.8%), this increase in the number of
survivors compared to the earliest reports of XDR-TB at this site
has allowed for an in-depth examination of correlates of their
survival.
Figure 2. Modifiable & Non-Modifiable Clinical Characteristics of XDR-TB Patients.
doi:10.1371/journal.pone.0031786.g002
Modifiable Characteristics for XDR-TB Survival
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characteristics independently associated with 180-day survival.
Not surprisingly, less advanced TB disease, reflected by higher
rates of negative sputum microscopy, was associated with
survival as was less advanced HIV disease, reflected by higher
CD4 cell counts. In addition, less organ system dysfunction,
manifested by lower clinical severity score, and concomitant
ART were associated with survival, the latter being strongly
correlated. These modifiable factors, if addressed by earlier TB
diagnosis, timely prescription of ART and addressing end-organ
damage manifest by abnormal laboratory values, could improve
XDR-TB survival even in the absence of new antituberculosis
medications.
Notably, the proportion of XDR-TB patients surviving to six
months in this study still remains considerably lower than other
reports. There are several possible reasons for this. First, unlike
other series, including those from other parts of South Africa,
[11,21] this study reviewed survival from the community hospital’s
perspective, where the XDR-TB diagnosis was made and not from
that of the specialty referral center to which patients would have to
be transferred for XDR-TB treatment, thereby averting survival or
lead time bias. Since these data demonstrate that a substantial
proportion of patients die before referral to TB specialty centers
and before XDR-TB therapy is even possible, this study gives a
more accurate picture of the overall mortality from XDR-TB. The
long lag time from suspected TB diagnosis to microbiological
Table 1. Demographic, Clinical, Sputum, and TB& HIV Treatment Characteristics Among Survivors & Non-survivors of XDR-TB
(n=142).
Survivors n=69
(% or IQR) Non-survivors n=73 (% or IQR) p-value
Demographic Characteristics at Diagnostic Sputum Collection
Median age (years) 34 (30–45) 34 (30–40) 0.83$
Women 40 (57.9) 50 (68.5) 0.191
Clinical & Laboratory Characteristics at Diagnostic Sputum Collection
HIV-infected (n=140) 61 (89.7) 68 (94.4) 0.301
Median days of survival 565 (384–774) 34 (18–90) ,0.0001J
Median months of TB symptoms prior to TB diagnosis (n=102) 3.0 (1.5–6) 3.0 (1–5) 0.24J
First episode of TB 23 (33.3) 39 (53.4) 0.021
Median weight (kg) (n=123) 51 (45.6–58.5) 47.5 (41–55) 0.11J
Bilateral disease on chest x-ray (n=104) 34 (70.8) 30 (53.6) 0.071
N Median hemoglobin (g/dL) (n=109)* Proportion of patients with
abnormal hemoglobin**
10.3 (9–11.9) 37/41 (90.2) 8.8 (7.4–10.3) 68/68 (100) ,0.001J
N Median creatinine (umol/L) (n=101)* Proportion of patients with
abnormal creatinine
67.0 (54.1–89) 14/38 (36.8) 80.0 (65.8–116) 31/63 (49.2) 0.008J
N Median alkaline phosphatase (IU/mL) (n=60)* Proportion of patients
with abnormal alkaline phosphatase
104.5 (78.9–143) 16/21 (76.2) 148 (86–212.6) 25/39 (64.1) 0.08J
N Median albumin (g/dL) (n=62)* Proportion
of patients with abnormal albumin
29.3 (25–33) 21/23 (91.3) 23.45 (18.1–28.3) 38/39 (97.4) 0.001J
Mean Laboratory Clinical Severity Index (LCSI) 1.28 2.22 ,0.0001$
Sputum Characteristics at Diagnostic Sputum Collection
Negative auramine smear (n=139) 42 (61.8) 15 (21.1) ,0.00011
Median weeks to positive sputum culture (n=137) 3 (2–3) 2 (2–2) 0.0002J
Median days to receipt of culture with DST results (n=106) 71 (61–92) 61 (51–75) 0.004J
Resistance to all 6 drugs tested (n=142) 49 (71) 62 (84.9) 0.041
TB Therapy
Receiving TB therapy at time of diagnostic sputum collection 42 (60.8) 53 (72.6) 0.211
Prior confirmed MDR-TB 9 (13) 3 (4.1) 0.0561
Mean number drugs in XDR-TB regimen (n=65) 6.25 5.6 0.22$
HIV Characteristics & Therapy
Baseline CD4 at diagnostic sputum collection (cells/mm
3) n=56 181 (60–260) 83.5 (32–169) 0.02$
Ever initiated ART 49 (80.3) 28 (41.2) ,0.00011
On ART prior to diagnostic sputum collection 30 (61.2) 20 (71.4) 0.371
Median months on ART prior to diagnostic sputum collection 4.2 (2.0–10.2) 3.4 (1.2–6.8) 0.22J
*not individually included in regression analysis.
**p,0.05.
$ttest.
1Chi-square.
JKruskal-Wallis.
doi:10.1371/journal.pone.0031786.t001
Modifiable Characteristics for XDR-TB Survival
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contributes to mortality and underlines the great need for rapid
TB diagnostics, particularly at the community level.
Secondly, unlike reports from other geographic regions, this
sample is overwhelmingly (91%) HIV-coinfected, with advanced
immunosuppression. Reports from Peru [7], Russia [8], Korea
Figure 3. Kaplan-Meier Estimates of XDR-TB Survival in HIV-Infected Patients (Months), n=129. a. Probability of survival according to
auramine smear status from time of sputum collection b. Probability of survival according to severity of organ dysfunction at sputum collection c.
Probability of survival according to baseline CD4 count at sputum collection d. Probability of survival according to use of ART from the time of
sputum collection.
doi:10.1371/journal.pone.0031786.g003
Table 2. Regression Analysis Associated with Survival among XDR-TB patients with HIV-coinfection (n=129).
Variable Crude Odds Ratio (CI) Adjusted Odds Ratio (CI)
Adjusted OR
p-value (Wald’s)
Negative auramine
smear result
7.78 (2.34, 25.85) 8.37 (1.84, 38.21) 0.006
Abnormal LCSI (Hemoglobin, Creatinine, Alkaline phosphatase,
Albumin)
0.48 (0.29, 0.79) 0.48 (0.22, 1.02) 0.056
CD4 count .200 cells/mm
3 at diagnostic sputum collection 5.5 (1.52, 19.85) 11.53 (1.11, 119.32) 0.04
Received antiretroviral therapy 5.62 (1.35, 23.52) 20.9 (1.16, 376.83) 0.04
doi:10.1371/journal.pone.0031786.t002
Modifiable Characteristics for XDR-TB Survival
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but in these series there were no or very few HIV-coinfected
patients, suggesting the key role of HIV-induced immune
suppression on XDR-TB mortality. Intermediate survival rates
have been reported in two other studies from South Africa, but
HIV prevalence was lower (47% and 70%, respectively) and CD4
counts were substantially higher (273 and 200 cells/mm
3,
respectively) than in the present series. [11,21] Thus, these data
strongly support that not only HIV infection, but the degree of
immunosuppression, contributes to XDR-TB mortality, suggesting
that earlier identification of HIV could improve outcomes in
coinfected patients.
Last, unlike other studies, only a small proportion of patients in
this series had been previously treated for confirmed MDR-TB
(8.5%). Series with higher rates of previous MDR-TB treatment
are likely to have monitored these patients more closely, possibly
contributing to longer survival and introducing observation bias
into survival estimates. Furthermore, the high proportion of
patients for whom XDR-TB was the first diagnosis of TB and the
low proportion with prior MDR-TB in this study suggests most
XDR-TB infections were acquired through primary transmission.
This is supported by the high proportion of streptomycin
resistance found among those who had not previously received
this medication. This differs markedly from another recent report
from South Africa in which most (72%) XDR-TB cases likely
resulted from acquired resistance during previous therapy for
confirmed MDR-TB [11]. This distinction emphasizes the
importance of determining the etiology of XDR-TB in different
geographical regions in order to prioritize appropriate manage-
ment and prevention strategies [23].
Opportunities for policy, programmatic, and clinical
intervention
Assessment of laboratory tests conducted at the time of sputum
collection identified several abnormalities for which relatively
simple clinical interventions could potentially improve survival.
The development of the composite LCSI in this study is
exploratory; thus the findings related to its use are provisional
but warrant further prospective evaluation. Though clinically
intuitive that dysfunction in multiple organ systems conveys a
worse prognosis, we confirm this for the first time among XDR-
TB patients. Improving nutritional supplementation for hypoal-
buminemia, transfusion for clinically significant anemia, and
correction of hypovolemia in patients with elevated creatinine, if
applied early and aggressively, may contribute to improved
survival. In addition to clinical interventions to modify high
mortality rates, the advanced stage of both TB and HIV can be
modified and survival potentially improved. Advanced TB and
HIV disease were associated with XDR-TB mortality within 180
days in this study, underlining the need for earlier case finding in
health care and community settings, use of rapid TB diagnostic
tests such as GenXpert [24], and earlier therapy for both
conditions. Data from this study suggest that there were ample
opportunities for earlier XDR-TB diagnosis and treatment;
diagnostic sputum culture was not obtained until a median of
four months after initiation of first-line TB therapy. Opportunities
were also likely missed for both earlier HIV testing and initiation
of ART.
Reliance on the traditional TB diagnostic positive AFB smear
missed half of the XDR-TB patients in this study and did so in
nearly 80% of non-survivors. Known to be less sensitive,
particularly in HIV-infected patients, an AFB smear that is
negative should not dissuade clinicians from ordering sputum
culture and DST in patients clinically suspected of having TB.
Particularly where MDR-TB and XDR-TB are prevalent, and
until newer molecular tests are widely available, culture should be
ordered during the initial assessment [25]. In this series, waiting
until patients had failed first-line antituberculosis therapy before
ordering a culture had disastrous consequences. The findings
support the current South African TB guidelines [15] recom-
mending smear and culture be sent simultaneously in HIV-
infected patients suspected of active TB. This recommendation,
however, is followed infrequently and operational research is
urgently needed to improve implementation while awaiting the
availability of new diagnostic methods [24,26].
From a treatment perspective, the provision of ART either
before sputum collection or after diagnosis of XDR-TB was
significantly associated with survival. It is important to note that
the retrospective study design and the case definition of survival
limit the interpretation of the data and the question of whether
ART improves survival or whether survival simply leads to more
opportunity for ART initiation should be studied prospectively.
Nonetheless, this finding validates other retrospective observation-
al studies with less immunosuppressed HIV-infected populations at
referral centers [11,21], suggesting that the effect of ART on
survival from XDR-TB is important. Furthermore, cohort studies
and randomized controlled trials confirm that ART during
treatment of drug-susceptible TB in coinfected patients reduces
mortality [27,28,29,30]. Indeed, other factors associated with
survival in the current study including that early TB disease
manifested by less severe disease and early HIV disease manifested
by high CD4 counts, also echo previous studies of drug susceptible
TB in South Africa [31,32,33,34]. Thus, ART may be even more
important in the setting of XDR-TB where few if any effective
antituberculosis therapies are available. In settings where both
HIV and TB are endemic and especially where XDR-TB results
from primary transmission, widespread and earlier ART initiation
may significantly reduce XDR-TB incidence and may contribute
to improved survival. The WHO has promoted the ‘‘3 I’s’’ for TB
control: infection control, isoniazid preventive therapy, and
intensive case finding [35]. Accumulating data including those
presented here demonstrate that ART is so critical to management
of TB/HIV-coinfected patients that ‘‘Initiation of ARVs’’ should
be considered the 4
th ‘I’.
Clinical management of XDR-TB in KwaZulu Natal province
and elsewhere is provided by experts in specialized TB referral
centers. Antiretroviral therapy, however, is often managed
separately by HIV specialists and is not well integrated with TB
care. Convergence of TB and HIV epidemics, however, requires
careful coordination to optimize outcomes for both conditions
[36,37]. Concomitant management of drug-resistant TB and HIV
have been recognized within international guidelines [38] and the
South African 2010 Guidelines [39] now make substantial strides
in expanding ART access to all patients with drug-resistant TB.
Diagnostics, staging, including CD4 cell count and viral load
testing simultaneous with sputum smears and cultures, and
therapy for both drug susceptible and drug-resistant TB and
HIV-coinfection should ideally occur in the same setting, by the
same practitioners. In one such integrated MDR-TB/HIV model
of care in South Africa, preliminary results show feasibility, patient
acceptability, medication tolerability, and excellent outcomes [40].
Further study is needed but more widespread implementation of
this integrated strategy is warranted.
We recognize limitations in our study. First, retrospective chart
reviews may introduce bias due to inadequately recorded or
missing clinical information. For the variables in the final
multivariate model of HIV+ patients, however, data was not
disproportionately missing among survivors and nonsurvivors.
Modifiable Characteristics for XDR-TB Survival
PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e31786Second, potential sampling bias may have occurred since only a
portion of all non-survivors were reviewed. If oversampling of one
or more characteristics occurred as a result, the correlates
associated with survival may be misleading. We do know,
however, that those reviewed were demographically representative
of the entire population of XDR-TB patients. Last, we recognize
that case control studies, such as the present one, can only provide
associations and cannot conclude causality. Additionally, in this
study, the creation of two patient groups, survivors and
nonsurvivors, may have artificially contributed to differences
observed in the study results. Prospective studies are needed to
confirm the actual effect of the modifiable characteristics identified
in the present study on survival.
Despite these limitations, this study represents the largest sample
of XDR-TB patients from a community-based, non-referral
hospital, contributes new information regarding the correlates of
survival, and identifies modifiable factors that are amenable to
improvement through changes in policy and clinical management
of patients with or at risk for XDR-TB. In order to improve
survival, health care administrators and TB and HIV clinicians
must work collaboratively to identify patients earlier, and integrate
diagnostic, therapeutic, and preventive activities.
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